Cigna Corporation

🇺🇸New York Stock Exchange
Back to all articles
Cigna Corporation stock analysis CI overview
Bullish +75

The Cigna Group (CI) CEO Change Timing May Come As Surprise to Some Investors, According to Barclays

- 📈 The Cigna Group (NYSE: CI) is currently trading at $269.66 with a projected 23.67% upside potential despite falling more than 15% over the previous year.

- 👤 CEO David Cordani is retiring as of March 3, 2026, to be succeeded by Brian Evanko, who previously served as CFO and COO.

- 🧔 Barclays notes that Evanko was always considered the natural successor due to his extensive institutional experience within the company.

- ⏰ The leadership transition timing may surprise investors because it coincides with the start of a multi-year transformation of the company's pharmacy benefit management (PBM) model.

- 💵 Cigna reaffirmed its 2026 earnings outlook, forecasting full-year consolidated adjusted income from operations of at least $30.25 per share.

- 🏥 The company expects pre-tax adjusted income for Evernorth to be at least $6.9 billion and for Cigna Healthcare to be at least $4.5 billion.

- 📊 Nearly 85% of analysts remained bullish on the stock as of March 9, 2026, viewing the changes as a reflection of strategic continuity amid industry pressures.

- 🏆 The Cigna Group has outperformed the broader healthcare plans sector, which declined by more than 30% over the same one-year period.

- 🤖 Analysts at Insider Monkey believe that while CI is a good investment, AI stocks may hold greater promise for delivering higher returns in shorter time frames.

- 📜 Cigna operates as a leading global health services provider focused on pharmacy benefits, healthcare solutions, and care management through its subsidiaries Evernorth Health Services and Cigna Healthcare.

Bullish Signals
  • Cigna Group (NYSE: CI) is included in the list of 11 best value stocks to invest in according to billionaires.
  • Nearly 85% of analysts remain bullish on the company as of March 9, 2026.
  • Despite a stock decline of more than 15% over the previous year, CI is currently trading at $269.66 with a 23.67% upside potential.
  • Cigna has outperformed the healthcare plans sector, which declined by more than 30% over the same period.
  • The company's CEO Brian Evanko brings extensive institutional experience and is highlighted as the natural successor to CEO David Cordani.
  • Evanko will be one of the youngest CEOs in the healthcare services industry, suggesting a fresh leadership perspective.
  • Cigna reaffirmed its long-term earnings outlook with a forecast for full-year consolidated adjusted income from operations of at least $30.25 per share.
  • The company expects pre-tax adjusted income for Evernorth of at least $6.9 billion and Cigna Healthcare of at least $4.5 billion.
  • Deutsche Bank has issued a Buy recommendation on Cigna (CI).
  • Piper Sandler continues to back the company's PBS strategy, issuing a minor PT cut while maintaining support.
Risk Factors
  • The timing of the CEO change is a concern as Cigna Group begins the first year of a multi-year transformation of its pharmacy benefit management (PBM) model, which Barclays notes may come as a surprise to some investors.
  • Despite the stock being included in 'best value' lists, analyst conviction shifts towards AI stocks, with the article suggesting AI stocks may hold greater promise for delivering higher returns within a shorter time frame compared to Cigna.
  • The article promotes alternative investments by directing readers to reports on an unnamed AI stock with purported "10,000% upside potential" and other high-growth strategies, implicitly suggesting Cigna offers inferior risk-adjusted returns.
  • Cigna faces a competitive landscape where the firm explicitly acknowledges that AI stocks are viewed as more promising alternatives for investors seeking performance, highlighting a potential opportunity cost.
Full Analysis
The Cigna Group (NYSE: CI) recently announced a significant leadership transition on March 3, 2026, with outgoing CEO David Cordani stepping down and Brian Evanko, the current COO and former CFO, set to succeed him. Barclays, along with other analysts like Deutsche Bank, views this change as strategic continuity rather than a disruption, noting Evanko's extensive institutional experience and his status as one of the youngest CEOs in the healthcare services industry. While nearly 85% of analysts remain bullish as of March 9, 2026, Barclays points out that the timing of the CEO change coincides with the first year of a multi-year transformation of the company's pharmacy benefit management (PBM) model, which might catch some investors off guard given the ongoing business model shifts. Despite the stock falling more than 15% over the previous year to reach a price of approximately $269.66, insiders and analysts see significant upside potential, with figures suggesting roughly 23.67% room for growth compared to the healthcare plans sector which has declined by over 30%. The company reaffirmed its full-year 2026 earnings outlook on March 3, forecasting consolidated adjusted income from operations of at least $30.25 per share. Specific divisional targets include pre-tax adjusted income of at least $6.9 billion for Evernorth Health Services and at least $4.5 billion for Cigna Healthcare, reinforcing the firm's confidence in its strategic direction amidst industry pressures and AI-related market discussions highlighted in the broader commentary.